Novogene Europe’s Post

Following recent news from Charles River Laboratories, regarding their continued investment into their Alternative Methods Advancement Project (AMAP), to reduce reliance on animal testing - we are thrilled to share a collaborative #genotoxicity publication between CRL, CN Bio and TwinStrand Biosciences. The publication demonstrates that Liver-on-a-chip is a promising tool for genotoxicity assessment. Click the link to learn more & congrats to all involved! #animalalternatives #organonchip #microphysiologicalsystem

In the high-stakes world of biotech, particularly within the rare disease sector, the journey from concept to cure is fraught with uncertainties. Companies like Synlogic and others, daring to proceed in the treacherous waters of Phase 3 clinical trials often face the harsh reality of failure, burning through significant capital with nothing to show but lessons learned. But it’s precisely these audacious endeavors that pave the way for groundbreaking therapies. This brings us to a critical crossroad in our industry’s approach to innovation and risk. Shouldn’t there be a mechanism to reward the courage and financial risk taken by companies and their investors, even when trials don’t meet their endpoints? The current model celebrates success but often overlooks the value of the attempt itself, which lays the groundwork for future breakthroughs. Incorporating a value proposition that accounts for these risks and costs in health technology assessments could revolutionize our approach to drug development. This isn’t about subsidizing failure; it’s about recognizing the indispensable role that risk-taking plays in advancing medical science. By reassessing how we value these efforts, we can ensure that companies continue to strive towards bringing new therapies to market, breathing life into the next wave of innovation. Let’s not forget, behind every failed trial is a potential stepping stone to success. If we want to keep pushing the boundaries of what’s possible in treating rare diseases, we need to give companies the ‘oxygen’ they need to survive the journey. It’s time to rethink how we reward risk in the quest for cures. #rare #raredisease #Biotech #RareDisease #Research #Healthcare #Economics

Kicked off with discussions at the workshop day with topics including: 💡 Workshop A - Unveiling the Protein Universe: Structure-Based Drug Design with NMR, X-Ray Crystallography, & Cryo-EM 💡 Workshop B - Navigating Protein Samples for Each Structural Technique to Optimize Protein Production & Supercharge Structure Determination 💡 Workshop C - Diving Deep into Data: Cultivating Data Acquisition & Management for Structural-Based Drug Design #SBDDSummit #structurebaseddrugdesign #drugdesign #cryoem #xraycrystallography #nmr #structuralbiology

Benchtalk 2023 Conference Recap ⏪ ⏪ Last week, Karchem Consulting had the pleasure of attending Benchtalk 2023 in Boston! Many thanks to Benchling for their effort in creating an opportunity to connect with other Benchling users and to gain inspiration, knowledge, and cutting-edge insights on leveraging the system to revolutionize R&D. Conference sessions were enlightening, ranging from CRISPR-Cas9 applications to the future of data-driven drug discovery.  We enjoyed listening to speakers from Verve Therapeutics, Genentech, Twist Bioscience, Editas Medicine, GV (Google Ventures), and more. Perhaps the highlight of the event– the unveiling of Benchling Connect and Benchling Bioprocess.  We’re looking forward to learning more about these features as they are available, and seeing how they can meet the needs of the modern-day laboratory environment. With systems that rapidly evolve like Benchling, it can be a full-time job keeping up with the latest releases and products.  Our team stays up to date on the latest features so you don’t have to.  If you’re looking for assistance implementing or optimizing your Benchling environment, reach out on Linkedin or contact us at https://lnkd.in/dVpU8qNm. Overall we look forward to utilizing these new tools and insights and seeing where #JeffyP will go next! #Benchtalk2023 #ELN #LIMS #tech #biopharma #drugdiscovery #conference #networking #bioprocess #data #RND #boston

A learning opportunity.

Integration is key when you want a #digitalpathology system that works seamlessly, and Lyell Immunopharma's Trevor Do will be sharing how Lyell's system meets the mark at #IndicaLabs' Bay Area UGM. https://lnkd.in/g6WeEd8i

The path to successful inventorship in drug discovery is rarely a straightforward one. The problem solving skill required from medicinal chemists can seem unending in the hit to candidate process and leads to the abandonment of many chemical series. What is required is a diverse tool box of strategies and the knowledge and experience to direct the appropriate approach, often gained through many years of trial and failure accompanied by a certain amount of success. The Domainex Synthesis group regularly compile some literature lessons that they have found helpful in the quest for orally bioavailable, potent and selective NCEs. Why not follow our page or contact us to sign up to our newsletter and regularly receive these updates and insights? #medchem #designmaketestanalyse

Have you registered for our upcoming in-lab demo yet? There's only one week left to secure your spot for the second session of our DispenCell & CloneSelect Imager Virtual Demo with SEED Biosciences, happening on Thursday, November 30, at 11 am EST. Not only will you learn how the bundle verifies monoclonality, provides gentler dispensing of previous cells, decreases FTE hours and more, but you'll also have the exclusive opportunity to ask the experts your most pressing questions. Register using the link below 👇 #singlecell #biotechnology #biopharma #automation

Stop screening & start synthesizing by leveraging the power of SYNTHIA™ retrosynthesis from MilliporeSigma. Register for your free SYNTHIA™ Lite trial access > https://lnkd.in/dZ_EjE39 Quickly find & easily navigate innovative and novel pathways for novel and published target molecules. #retrosynthesis #drugdiscovery #organicchemistry #medicinalchemistry

#Singlecell Omics is a hot topic for #FOGBoston next week, and Scale Biosciences can't wait! Don't miss our talk at the Live Lounge on June 12, and be sure to join us at booth 10 to talk about #methylation, #RNAseq, #CRISPR, and more, brought to you, finally, at SCALE.